Merlin BioMed was a New York City based investment advisor. Founded in 1998 by Dr. Stuart T. Weisbrod, Merlin BioMed encompasses several hedge funds. Managed by healthcare professionals, they invest in biotechnology, pharmaceuticals, medical devices and healthcare sectors.
Merlin BioMed has made investments in CymaBay Therapeutics, Gemin X Pharmaceuticals, Calypso Medical, EUSA Pharma, RenaMed Biologics, GeneLabs Technologies, FibroGen, ARYx Therapeutics, Salient Surgical Technologies, ARIAD Pharmaceuticals, Ventaira Pharmaceuticals, Confluent Surgical, De Novo Pharmaceuticals, Skila and Health Hero Network.
They exited their investments in FibroGen, CymaBay Therapeutics, Salient Surgical Technologies, Gemin X Pharmaceuticals, ARYx Therapeutics, Calypso Medical, EUSA Pharma, ARIAD Pharmaceuticals, Genelabs Technologies, Confluent Surgical and Ventaira Pharmaceuticals.